Literature DB >> 7590425

Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH.

T G Reilly1, S G Mann, M Z Panos, R P Walt.   

Abstract

To investigate the relative abilities of low doses of famotidine and cimetidine to raise intragastric pH after a single postprandial evening dose, 16 healthy volunteers were recruited to a four period crossover trial of famotidine 10 mg, cimetidine 100 mg and 200 mg compared with placebo. Intragastric pH was monitored between 1800 and 0730 with a nasogastric pH electrode. Median gastric pH rose from 1.35 (interquartile range 1.1-1.65) with placebo to 1.95 (1.6-5.35, p < 0.001 Friedman rank) after dosing with famotidine 10 mg, to 1.46 (1.3-2.0, 0.05 < p < 0.1) after cimetidine 200 mg, and remained 1.35 (1.1-1.6, p > 0.2) after cimetidine 100 mg. Intragastric pH was above 3 for 34% (p < 0.005) of the time after dosing with famotidine, compared with 13.6% (p > 0.2) after cimetidine 200 mg, 9.5% (p > 0.2) after cimetidine 100 mg, and 4.7% after placebo. The rise of intragastric pH after famotidine 10 mg is significantly greater than that after either 200 mg or 100 mg cimetidine when the drugs are used postprandially.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7590425      PMCID: PMC1382810          DOI: 10.1136/gut.37.3.325

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  The timing of the evening meal affects the pattern of 24-hour intragastric acidity.

Authors:  S Lanzon-Miller; R E Pounder; R L McIsaac; J R Wood
Journal:  Aliment Pharmacol Ther       Date:  1990-10       Impact factor: 8.171

2.  Effects of low-dose cimetidine on nocturnal acid secretion in healthy subjects.

Authors:  G Acton; C Broom; K Wareham; J Laroche; D Burnham; C Friedman
Journal:  Aliment Pharmacol Ther       Date:  1991-02       Impact factor: 8.171

3.  Effect of food on H2-receptor blockade in normal subjects and duodenal ulcer patients.

Authors:  H S Merki; F Halter; C Wilder-Smith; P Allemann; L Witzel; M Kempf; J Roehmel; R P Walt
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

4.  Inhibition of nocturnal acid secretion in duodenal ulcer patients by an H-2 histamine antagonist-cimetidine. A controlled double-blind investigation.

Authors:  D Hollander; Z Hossain; A M Sufi
Journal:  Am J Dig Dis       Date:  1976-05

5.  Pharmacodynamics and dose-response relationship of famotidine: a double-blind randomized placebo-controlled trial.

Authors:  O L Laskin; P M Patterson; S Shingo; K C Lasseter; E C Shamblen
Journal:  J Clin Pharmacol       Date:  1993-07       Impact factor: 3.126

6.  Bioavailability of cimetidine in man.

Authors:  S S Walkenstein; J W Dubb; W C Randolph; W J Westlake; R M Stote; A P Intoccia
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

7.  Circadian differences in pharmacological blockade of meal-stimulated gastric acid secretion.

Authors:  S W Sanders; J G Moore; G M Day; K G Tolman
Journal:  Aliment Pharmacol Ther       Date:  1992-04       Impact factor: 8.171

Review 8.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

9.  Total 24-hour gastric acid secretion in patients with duodenal ulcer. Comparison with normal subjects and effects of cimetidine and parietal cell vagotomy.

Authors:  M Feldman; C T Richardson
Journal:  Gastroenterology       Date:  1986-03       Impact factor: 22.682

10.  Twenty-four-hour intragastric pH-metry: H2-receptor antagonist restoration of nightly gastric spontaneous alkalinization in duodenal ulcer healing.

Authors:  A Bianco; M Cagossi; R Piraccini; A V Greco
Journal:  Riv Eur Sci Med Farmacol       Date:  1992 Sep-Oct
View more
  1 in total

1.  Decrease of intragastric acidity in healthy subjects dosed with ranitidine 75 mg, cimetidine 200 mg, or placebo.

Authors:  Mark I Hamilton; Judy Sercombe; Roy E Pounder
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.